Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib in pediatric relapsed or refractory solid tumors
NCT07773454Phase 1Not yet recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Sep 2026
- Primary completion
- Jul 2028
01
Overview
Phase 1, open-label, single-arm trial of zanzalintinib in solid tumor, sponsored by Exelixis, Inc. Primary endpoints: Number of Participants With Dose-Limiting Toxicities and Number of Participants With Treatment-Emergent Adverse Events up to 8 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
zanzalintinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07773454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07773454.